Gastric Adenocarcinoma
Conditions
Keywords
Gastric cancer, HER2, trastuzumab, prognosis
Brief summary
Trastuzumab plus chemotherapy is an effective therapy in HER2 positive advanced gastric cancer (AGC). However, the efficacy of routine trastuzumab therapy and its association with clinicopathologic factors remain unclear. The object of the study is to determine whether the addition of trastuzumab to first-line chemotherapy improves efficacy compared with chemotherapy alone in HER2 positive AGC.
Detailed description
A total of 98 patients with HER2 positive AGC were enrolled in this prospective observational study. All patients were treated with trastuzumab plus chemotherapy as the first line therapy. Efficacy and safety of trastuzumab were analyzed, clinical and pathological data were collected to evaluate the potential prognostic factors on progressive free survival.
Interventions
DRUGH+CT
All patients were treated with trastuzumab plus chemotherapy as the first-line therapy. There were no protocol-specified chemotherapy regimens. This is a prospective observational study. Efficacy and safety of trastuzumab were analyzed, clinical and pathological data were collected to evaluate the potential prognostic factors on progressive free survival.
Sponsors
Shanghai Zhongshan Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. pathology and medical imageology proven advanced gastric adenocarcinoma, inoperable; 2. received trastuzumab plus chemotherapy as the first-line palliative chemotherapy; 3. with measurable lesion with a diameter 20 mm using conventional computed tomography (CT) or magnetic resonance imaging (MRI) scans or 10 mm using spiral CT scans; 4. Eastern Cooperative Oncology Group performance status (ECOG PS ) of 0-2; 5. left ventricular ejection fraction(LVEF) more than 50 percents; 6. sufficient bone marrow, liver and renal function.
Exclusion criteria
1. received previous systemic therapy for advanced disease (except adjuvant/neoadjuvant chemotherapy completed at least 6 months before enrollment); 2. trastuzumab based adjuvant/neoadjuvant therapy; 3. treatment with any other anticancer therapy (lapatinib, immunotherapy, etc); 4. patients with heart failure, coronary artery disease or myocardial infarction within the previous 6 months. 5. trastuzumab based first line therapy started beyond 4 weeks from the first diagnoses of AGC.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| OS | 8 years | OS was defined as time from the beginning of first line therapy to death |
| PFS | 8 years | PFS was measured from the start of first line therapy to the date of progressive disease or death, with censoring of patients who were lost to follow-up. |
Countries
China
Outcome results
None listed